Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.74Last Year’s EPS
-1.02Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -18.00%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted several significant achievements such as the initiation of the ECLIPSE Phase III program, a strong financial position, and positive updates in the oncology portfolio. However, these were tempered by financial losses, strategic challenges with Alnylam, and dependency on partnerships for the hepatitis B program's progress.Company Guidance
During the first quarter of 2025, Vir Biotechnology provided detailed guidance on its strategic focus and development progress across its infectious disease and oncology portfolios. The company highlighted the initiation of the ECLIPSE Phase III registrational program for hepatitis delta virus (HDV), enrolling the first patient in ECLIPSE-1. They estimate about 7 million active viremic HDV RNA-positive patients globally, with 61,000 in the U.S. and 113,000 in the EU and U.K. Vir highlighted the severe outcomes for HDV patients, noting more than 50% succumb to liver-related death within 10 years without FDA-approved treatments. The company emphasized its strong financial position, ending the quarter with approximately $1 billion in cash, ensuring a cash runway into mid-2027. Key financial metrics included R&D expenses of $118.6 million, driven by a $30 million payment to Alnylam, and SG&A expenses of $23.9 million. The company's oncology progress was marked by advancements in its PRO-XTEN Dual Masked T-Cell Engager program, with encouraging results in colorectal cancer and prostate cancer trials, and the initiation of the Phase I study for VIR-5525 targeting EGFR-expressing tumors. Vir also noted potential partnerships to maximize value from its PRO-XTEN platform.Initiation of ECLIPSE Phase III Program
The ECLIPSE Phase III registrational program for hepatitis delta virus infection was successfully initiated, with the first patient enrolled in ECLIPSE-1 during the first quarter. This milestone positions Vir Biotechnology to potentially establish a new standard of care.
Strong Financial Position
Vir Biotechnology maintains a strong cash position with approximately $1 billion in cash, cash equivalents, and investments, providing a cash runway extending into mid-2027.
Positive Oncology Portfolio Updates
Encouraging data from the PRO-XTEN Dual Masked T-Cell Engager program, with notable partial response rates and favorable safety profiles in HER2-positive colorectal cancer patients and prostate cancer patients.
Advancement in HIV Cure Program
A broadly neutralizing antibody has advanced to development candidate status in the HIV cure program, demonstrating progress in infectious disease immunology.
---
VIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $5.61 | $5.41 | -3.57% |
Feb 26, 2025 | $9.20 | $8.11 | -11.85% |
Oct 31, 2024 | $7.49 | $9.26 | +23.63% |
Aug 01, 2024 | $9.73 | $9.21 | -5.34% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vir Biotechnology (VIR) report earnings?
Vir Biotechnology (VIR) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Vir Biotechnology (VIR) earnings time?
Vir Biotechnology (VIR) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VIR EPS forecast?
VIR EPS forecast for the fiscal quarter 2025 (Q2) is -0.74.
---